Published in New England Journal of Medicine · View the paper (DOI)
A single-dose of the antiviral drug peginterferon lambda reduced the risk of hospitalization or Emergency Department visit due to COVID-19 by half in high-risk patients. The treatment was effective across different variants of concern, including Omicron, and showed minimal side effects.
Coverage from 2 institutions